PALO ALTO, Calif., Sept. 25 /PRNewswire/ -- Data supporting the long-term safety and effectiveness of renal sympathetic denervation (RDN) in treating patients with chronic hypertension were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, California. The data were presented at a late-breaking trial session and showed that patients in the study maintained a clinically significant reduction in blood pressure at one -year following treatment.
The study’s co-principal investigator, Professor Henry Krum, (Director, Center of Cardiovascular Research & Education in Therapeutics, Monash University, Melbourne Australia) reported that the simple, 40 minute procedure safely produced a mean blood pressure reduction of -27/-17 mmHg at 12 months in the study cohort. These findings suggest that the single, catheter-based intervention may achieve a durable, clinically important reduction in blood pressure in this very difficult to treat population.
Commenting on these results, Professor Krum stated, “I am very excited by these latest findings. These data demonstrate that the reductions in blood pressure we observed at 12 months in our initial Lancet paper have been found to be durable amongst a much larger cohort of patients who have now completed the study.”
About Ardian
Ardian, Inc., headquartered in Palo Alto, California, is a pioneering, private, clinical-stage medical device company developing a novel catheter-based treatment for diseases related to sympathetic hyperactivity, including hypertension, chronic kidney disease, metabolic syndrome and heart failure. These interdependent disease states represent a significant, escalating global health issue. Ardian is the eighth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. For more information about the Symplicity((R)) Catheter System(TM), Ardian or its clinical trials, please visit www.ardian.com.
Ardian, Inc.
